secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0000950170-25-034580
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio Q4 net loss $0.32/share, cash $176.3M; expects ADI-001 LN data in 1H25
--------------------------------------------------------------------------------

- Q4 2024 net loss $28.7M ($0.32/share) vs. $29.5M ($0.69/share) in Q4 2023; full year net loss $117.1M.
- Cash, cash equivalents and short-term investments $176.3M as of Dec 31, 2024; expected to fund ops into 2H26.
- Phase 1 trial of ADI-001 in autoimmune diseases: LN patient preliminary data expected 1H25; enrollment for SLE, SSc, IIM, SPS to start 2Q25.
- ADI-270 Phase 1 in ccRCC: preliminary data expected 1H25; first patient dosed Dec 2024.
- Received FDA Fast Track Designation for ADI-001 in refractory SLE with extrarenal involvement and SSc (Feb 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017025034580/0000950170-25-034580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017025034580/acet-20250306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-034580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer